Granulocyte colony-stimulating factor - Shire Pharmaceuticals

Drug Profile

Granulocyte colony-stimulating factor - Shire Pharmaceuticals

Alternative Names: G-CSF - Shire Pharmaceuticals; G-CSF - Transkaryotic Therapies; Gene-activated G-CSF; Gene-activated granulocyte colony-stimulating factor

Latest Information Update: 02 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Neutropenia

Most Recent Events

  • 02 May 2007 No development reported - Phase-I for Neutropenia in USA (Injection)
  • 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
  • 23 Aug 2004 This compound is available for licensing (http://www.transkaryotictherapies.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top